Mutations in SMARCAL1 cause Schimke Immuno-Osseous Dysplasia (SIOD), an autosomal recessive multisystem developmental disease characterized by growth retardation, T-cell deficiency, bone marrow failure, anemia and renal failure. SMARCAL1 encodes an ATP-driven annealing helicase. However, the biological function of SMARCAL1 and the molecular basis of SIOD remain largely unclear. In this work, we cloned the zebrafish homologue of the human SMARCAL1 gene and found that smarcal1 regulated cell cycle progression. Morpholino knockdown of smarcal1 in zebrafish recapitulated developmental abnormalities in SIOD patients, including growth retardation, craniofacial abnormality, and haematopoietic and vascular defects. Lack of smarcal1 caused G0/G1 cell cycle arrest and induced cell apoptosis. Furthermore, using Electrophoretic Mobility Shift Assay and reporter assay, we found that SMARCAL1 was transcriptionally inhibited by E2F6, an important cell cycle regulator. Over-expression of E2F6 in zebrafish embryos reduced the expression of smarcal1 mRNA and induced developmental defects similar to those in smarcal1 morphants. These results suggest that SIOD may be caused by defects in cell cycle regulation. Our study provides a model of SIOD and reveals its cellular and molecular bases.
Introduction
Schimke Immuno-Osseous Dysplasia (SIOD) is an autosomal recessive multisystem developmental disease characterized by growth failure with short stature, T-cell deficiency with recurrent infection, bone marrow failure, anemia, renal failure, cardiovascular disease, hypertension and stroke in the first decade of the patient's life (Boerkoel et al., 2002; Bokenkamp et al., 2005; Clewing et al., 2007b) . SIOD is caused by the mutations in SMARCAL1 (swi/snf related, matrix associated, actin-dependent regulator of chromatin, subfamily a-like 1), which encodes a chromatin remodeling protein (Coleman et al., 2000) . However, the function of SMARCAL1 and the cellular and molecular mechanisms underlying SIOD remain to be elucidated.
SMARCAL1 is homologous to the SWI/SNF chromatin remodeling proteins and the SF2 family of helicases (Boerkoel et al., 2002; Coleman et al., 2000) . SWI/SNF family complexes regulate DNA repair, DNA replication, DNA recombination and transcriptional activity through DNA methylation, DNA acetylation, ubiquitination and phosphorylation, consequently regulating cell cycle (Gangaraju and Bartholomew, 2007; Huang et al., 2003; Kadam and Emerson, 2002) . SWI/SNF molecules such as excision repair cross-complementation (ERCC), α thalassemia X linked mental retardation (ATRX), brahma-related gene 1 (BRG1) and brahma (BRM) are involved in many developmental processes including cell proliferation, differentiation, apoptosis and homeostasis. Mutations in these genes cause tumorigenesis and human developmental diseases (Cho et al., 2004; Huang et al., 2003; Wang et al., 2007) . SMARCAL1 is an ATP-driven annealing helicase (Yusufzai and Kadonaga, 2008) , but its cellular function has not been examined. The large number of tissue and organ defects in SIOD patients suggests that SMARCAL1 plays an array of essential roles during development. Clinical studies of SIOD show that patients have normal UV sensitivity and rates of chromosome breakage, indicating no defect in p53-dependent DNA repair following gamma radiation (Boerkoel et al., 2000) . However, patients show defects in T-cell proliferation in response to mitogens such as interleukin-2, phytohaemagglutinin and concanavalin A. Anemia patients do not respond to erythropoietin. Patients with bone marrow failure do not respond to stem cell factor and those with growth retardation are not improved with growth hormone supplementation Developmental Biology 339 (2010) 89-100 (Boerkoel et al., 2000) . Those clinical findings imply that SIOD is mainly due to dysfunction in cell proliferation. Besides, some other aspects of SIOD may be related to the defects in cell differentiation, cell survival, cell growth and homeostasis and other developmental processes (Boerkoel et al., 2002; Clewing et al., 2007a; Elizondo et al., 2006) , indicating that SMARCAL1 is involved in SIOD through complicated mechanisms.
An animal model greatly facilitates the study of SMARCAL1 functions and the mechanisms underlying SIOD. However deletion of mouse Smarcal1 and drosophila homologues Marcal1 do not phenocopy the symptoms of SIOD patients (KS Cho et al., in preparation) . The external and rapid development and optical clarity during embryogenesis make zebrafish a powerful vertebrate model for in vivo dissecting mechanisms of clinically relevant developmental processes and diseases, particularly hematopoiesis, angiogenesis and T-cell development (Amatruda and Zon, 1999; Dooley and Zon, 2000; Langenau and Zon, 2005; McReynolds et al., 2007) , all of which are impaired in SIOD. Gene knockdown by morpholino oligonucleotides (MO) has been demonstrated to be an efficient method of gene targeting during early development of zebrafish (Gamse et al., 2002; Nasevicius and Ekker, 2000) .
In the present study, we cloned the zebrafish homologue of the human SMARCAL1 gene and found that deficiency of zebrafish smarcal1 caused developmental abnormalities like those found in SIOD patients. Down-regulation of smarcal1 expression caused cell proliferation defects with the cell cycle arrested at G0/G1 stage, and induced cell apoptosis. Furthermore, we found that smarcal1 is a direct target of cell cycle regulating transcription factor E2F6. These results shed light on the function of smarcal1 and the cellular and molecular bases for SIOD.
Materials and methods

Zebrafish strains
AB and Tg (fli1:GFP) zebrafish were obtained from Zebrafish International Resource Center (Eugene, Oregon, USA). Fish were housed in an automatic fish housing system (ESEN, China) at 28°C.
5′and 3′ RACE
Total RNA was extracted from the adult wild-type (WT) zebrafish head. The TakaRa RACE cDNA amplification kit was used according to the protocol provided by the manufacturer to perform 5′ and 3′ RACE (rapid amplification of cDNA ends). The 5′ RACE primers are outside 5′-ACTTTACCGCGTACTTCAAATG-3′ and inside 5′-GGCATGCGCATTT-CAATATA-3′; 3′RACE primers are outside 5′-CCATGCAGACCTCATCC-TAGT-3′ and inside 5′-CAAAAGCATTCCCTCCAAA-3′. The RACE products were cloned into pMD18-T vector (TakaRa, Dalian, China) and sequenced.
Morpholinos
Antisense smarcal1 (ATG-blocking) MO1 TTCTGGAGTCAGACTCA-CAGACATC, smarcal1 (splice-blocking) MO2 GCTGAGTCTGTAAAGAT-GAGCATAA, mdm2 MO CTCTGTTGCCATTTTGGTAGTTATC and p53 (ATG-blocking) MO GCGCCATTGCTTTGCAAGAATTG (Gene Tools, Philomath, OR, USA) were designed. The standard control MO was used as a control. One nl (8 ng) smarcal1 MO1, smarcal1 MO2, p53 MO, 3 ng of mdm2 MO or equal amount of control MO was microinjected into each 1-2 cell stage embryo.
RT-PCR
RNeasy Mini kit (QIAgen) was used to isolate total RNA from ten uninjected WT embryos and ten embryos injected with 1 nl MO. After treatment with DNase, 2 μg RNA was reverse-transcribed using Moloney murine leukemia virus (MMLV) Reverse Transcriptase (Promega). TakaRa Taq (TakaRa) was used for PCR for 30 and 26 cycles with smarcal1 primers and β-actin primers, respectively. Smarcal1 primers for 453 bp product are 5′-TCAAACCTCTGGAAGG-GATG-3′ (sense) and 5′-CTCTCTGGAAAGGCATGAGG-3′ (antisense). Smarcal1 exon1/exon4 primers are 5′-TTGTGTCAGTAAGCGCCTGT-3′ (sense) and 5′-CATCCCTTCCAGAGGTTTGA-3′ (antisense). β-actin primers for 559 bp product are 5′-CACCTTCTACAATGAGCTGCGTGTT-3′ (sense) and 5′-GATACCGCAAGATTCCATACCCAAG-3′ (antisense). Human SMARCAL1 primers are 5′-AGGGGAGACGTAAAGCTGTCC-3′ (sense) and 5′-AGACCATCCAAGCCATCTGC-3′ (antisense). Human β-ACTIN primers are 5′-TGGATCAGCAAGCAGGAGTATG-3′ (sense) and 5′-TCAAGAAAGGGTGTAACGCAACT-3′ (antisense).
Real-time RT-PCR
Total RNA from WT and MO injected embryos was extracted using the RNeasy Mini kit (QIAgen, Germany). The amount of reversely transcribed cDNAs was normalized with the real-time ABI 7500 Cycler using β-actin as a reference. Primer sequences are listed in Table 1 .
Constructs
The full-length human SMARCAL1, zebrafish smarcal1, zebrafish silent mutation smarcal1 and dp1 were cloned into pcDNA3.1 V5/His C by RT-PCR. Zebrafish smarcal1 5′UTR-5′cds was cloned into pEGFP-1. Human SMARCAL1 reporter plasmids were cloned into pGL3. The 453 bp zf smarcal1 PCR product was cloned into pGEM-T vector for Table 1 Real-time PCR primer sequences.
Gene
Acc. no. Forward primer Reverse primer
whole-mount in situ hybridization. The primers are listed in Table 2 .
In situ plasmids of rag1 and βE1-globin were obtained from Dr. R. Patient (Gering and Patient, 2005) , and gata1, gata2, l-plastin, pu.1 and mpo plasmids were obtained from Dr. N. Itoh (Yamauchi et al., 2006) . E2F1-5 expression constructs were obtained from Dr. R. Bernards and E2F6 construct was obtained from Dr. S. Gaubatz.
Whole-mount in situ hybridization (WISH)
WISH was performed as described (Koshida et al., 1998) . Digoxigenin (Roche, Mannheim, Germany) labeled cRNA probes were synthesized from linearized plasmids by in vitro transcription. Stained embryos were imaged with Olympus SZX9 Zoom Ztereo Microscope (Japan).
Smarcal1 mRNA rescue experiments
The capped full-length smarcal1RNA with silent mutations was synthesized using a T7 RNA polymerase and mMessage mMachine high-yield capped RNA transcription kit, according to the manufacturer's protocols (Ambion, Austin TX). For the rescue experiment, each 1-2 cell stage embryo was injected with 200 pg synthesized RNA.
Analysis of cell cycle
To analyze cell proliferation in the zebrafish, embryos were incubated with 10 mM bromodeoxyuridine (BrdU) as described previously (Shepard et al., 2004) and were fixed with 4% paraformaldehyde (PFA). Then whole-mount immunofluorescence was performed with 1:10 anti-BrdU antibody (Roche) and the secondary antibodies conjugated to fluorescein (1:10) according to standard protocols (Shepard et al., 2004) . The G2/M phase cells were detected by immunohistochemistry using a rabbit polyclonal anti-phosphorylated histone H3 (pH3) antibody (1:400, Cell Signaling, USA) and 1:500 Alexa red as described previously (Maroon et al., 2002) .
Apoptotic cells were determined with the TMR-RED in situ cell death detection kit (Roche) as previously described . The fluorescent signal was visualized and imaged using a Zeiss LSM510 microscope. Z-stack was superimposed using the extended focus feature of Zeiss LSM Image Examiner Version 3.2.0.115 software.
Fluorescence Activated Cell Sorting (FACS) was performed according to a standard protocol (Shepard et al., 2004) . Twenty 2 dpf embryos were disaggregated in 500 μl 10% FCS containing DMEM, and the cell suspensions were passed through a 70 μm filter. After being spun at 400g for 10 min at 4°C, liquid was removed. Then cell pellets were re-suspended in 2 ml propidium iodide (PI) solution containing 2 μg RNAase, and incubated in the dark at room temperature for 30 min. Then the cells were immediately analyzed on FACS Calibur (BD, USA).
Alcian blue cartilage staining
Cartilage was stained with Alcian Blue using a modified protocol (Robu et al., 2007) . Zebrafish larvae were fixed in 4% PFA, and stained with 0.1% Alcian blue (Sigma) in 70% ethanol and 0.37% hydrochloric acid for overnight at 4°C. Then embryos were bleached with 3% H 2 O 2 and 1% KOH for 4 h.
O-dianisidine staining
For staining of hemoglobin, embryos were treated in freshly prepared O-dianisidine mixture of 2.0 ml o-dianisidine (Sigma, 100 mg/70 ml of ethanol), 0.5 ml of 0.1 M acetate buffer (pH 4.7), 2.0 ml of deionized water, and 0.1 ml of hydrogen peroxide (30%) ) for 15 min and then fixed in 4% PFA (Iuchi and Yamamoto, 1983) . Embryos were dehydrated in methanol and cleared in 2:1 benzyl benzoate: benzyl alcohol solution (Ransom et al., 1996) .
Western blot analysis
Embryos were homogenized in 2× SDS sample buffer and boiled for 5 min. Ten micrograms of protein was separated by 10% SDS-PAGE and transferred to PVDF membrane, blocked for 1 h at room temperature in 5% non-fat dried milk/PBS-T. 1:2000 of anti-V5 (Invitrogen, USA) and HRP-conjugated secondary antibody were incubated with membrane for 1 h at room temperature. The membrane was then washed with PBS-T twice for 10 min each time, incubated with HRP-conjugated secondary antibody for 30 min at room temperature, and washed with PBS-T twice for 10 min. The signals were detected by ECL Plus Western Blotting Detection System according to the manufacturer's specifications (Amersham, Little Chalfont Buckinghamshire, England).
Electrophoretic mobility shift assay (EMSA)
The nuclear protein was extracted from E2F1-6 and dp1 cotransfected 293T cells. The sequences of biotin labeled probes are as follows:
Site A 5′-GGCTCTGCAGTCGCGCCTGGGGTCAGGGC-3′ Site B 5′-GGAGTGGGGCGTGGCGCCCGCTTACCTTG-3′ Site C 5′-GGGCGTCCATGGCGGAATGGATTTATGG-3′ EMSA was carried out according to a previous report (MacLachlan and El-Deiry, 2002) using a kit from Pierce (Rockford, IL, USA). Two Table 2 Primer sequences used in PCR for constructs.
Construct
5′ primer 3′ primer
a Bold characters indicate mutated nucleotides.
hundred times 4 pmol of unlabeled probe was used to confirm the specificity of the binding.
Reporter assay E2F1-6 and dp1 expression plasmids were co-transfected with reporter constructs. Transfection efficiencies were normalized by combining 0.5 μg of the relevant plasmids with 0.5 μg of reporter plasmids and 0.1 μg of pREP7 (Renilla luciferase) reporter . All transfections included 1.1 μg of total plasmids and 2 μl Lipofectamine 2000 (Invitrogen, Carlsbad, CA) per 0.5 ml of DMEM. Transfection solution was added to 293T cells for 4 h and then was replaced by culture medium. The cells were harvested for determination of luciferase activity 48 h later using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). The transfection efficiency was normalized by Renilla luciferase activity. All the transfection experiments were performed in triplicate and repeated at least two times.
Phylogenetic tree construction
The phylogenetic tree was constructed by aligning the amino acid sequences of most published Smarcal1 proteins with neighborjoining (Kumar et al., 2004) and maximum likelihood algorithms (Felsenstein, 2008) . The accession numbers of proteins used in the phylogenetic analysis are: Homo sapiens NP_054859.2, Pan troglodytes XP_516076.2, Macaca mulatta XP_001086469.1, Canis familiaris XP_536062.2, Bos Taurus NP_788839.1, Rattus norvegicus NP_001101692.1, Mus musculus NP_061287.1, Xenopus laevis NP_001089668.1, Xenopus tropicalis NP_001072923.1, Drosophila melanogaster NP_608883.1, Caenorhabditis elegans NP_498401.2.
Statistical analysis
Data analyses were performed using SPSS12.0 for Windows statistical program. All data were presented as means ± SE. Statistical analysis was done by one-way analysis of variance (ANOVA). Differences were considered significant when P b 0.05.
Results
Cloning and expression of zebrafish smarcal1
By searching the Ensemble database (http://www.ensembl.org/ Danio_rerio/blastview) with amino acid sequences of human SMAR-CAL1, we obtained one zebrafish smarcal1 expressed sequenced tag sequence (XM_001334615). We then isolated the full-length complementary DNA from adult zebrafish head cDNA with 5′ and 3′ RACE. A 3083-bp zebrafish smarcal1 was obtained, in which a poly(A) tailing signal AATAAA is located at the 3′ terminus from nucleotide 3055 to 3060. Zebrafish smarcal1 cDNA has been deposited in GenBank under the accession no. EU655703.
Using the zebrafish smarcal1 cDNA sequence to BLAST the Ensemble Zebrafish Genomic Sequence Project database, we found that the gene is located on Chromosome 20. Full-length zebrafish smarcal1 encodes a putative Smarcal1 protein of 807 amino acids. Sequence similarity comparison indicated that zebrafish putative Smarcal1 protein has 62.2% identity and 78.5% similarity to human SMARCAL1. Zebrafish Smarcal1 has all domains found in mammalian SMARCAL1 proteins (Fig. 1A) , including two HepA-related protein (HARP) domains at N-terminus that exhibit single-stranded DNAdependent ATPase activity, one SNF2 family N-terminal (SNF2_N) domain that involves in transcription regulation, DNA repair, DNA recombination and chromatin unwinding, as well as one helicase superfamily C-terminal (Helicase_C) domain near the C terminus ( Supplementary Fig. S1 ).
A phylogenetic tree was constructed by aligning the amino acid sequences of most published Smarcal1 proteins with neighbor-joining (Kumar et al., 2004) and maximum likelihood algorithms (Felsenstein, 2008) . Zebrafish Smarcal1 is conserved within vertebrates (Fig. 1B) . Comparison between zebrafish Smarcal1 and its homologues in other species shows that it shares 78.5%, 68%, 69%, 74.4%, and 76.5% similarity to human, mouse, rat, X. laevis and X. tropicalis Smarcal1, respectively. Taken together, smarcal1 gene is structurally conserved among zebrafish and mammals.
With use of RT-PCR, smarcal1 transcript was readily detected through 1-cell stage to the adult (Fig. 1C) . Whole-mount in situ hybridization (WISH) confirmed the presence of maternal smarcal1 mRNA at 1-cell stage embryos ( Supplementary Fig. S2A ). The expression was retained at a high level during blastula and gastrulation, which is at approximately 6 h post-fertilization (hpf) ( Supplementary Fig. S2B, C) . Around segmentation stages, the smarcal1 transcript, presumably the zygotic mRNA, appeared in a ubiquitous manner, and was subsequently enriched in the central nervous system (CNS) and eyes as well as the intermediate cell mass (ICM) from the 18-somite stage onwards (Supplementary Fig. S2D, G) .
Knockdown of smarcal1 causes abnormal development in zebrafish
To mimic SIOD symptoms, we designed two MOs to knock down zebrafish smarcal1. MO1 is against zebrafish smarcal1 ATG to block smarcal1 protein translation, and MO2 is against intron1 and exon2 junction to block the splice of smarcal1 mRNA ( Fig. 2A) . To assay the efficiency of smarcal1 MO1, we first made an expression construct that links smarcal1 5′ UTR and 5′ cds to GFP. Injection of in vitro transcribed mRNA into 1-2 cell stage embryos strongly induced GFP signal at 24 hpf (Fig. 2B) . However, GFP signal was significantly inhibited by co-injection with smarcal1 MO1 (Fig. 2B ). To further confirm MO1 efficiency, we made an expression construct of full coding region of zebrafish smarcal1 with V5/His tags. Western blot analysis showed that injection of in vitro transcribed mRNA into 1-2 cell stage embryos (200 pg/embryo) efficiently induced Smarcal1 protein at 24 hpf (Fig. 2C) . By co-injecting it with smarcal1 MO1 (8 ng/embryo), the signal was significantly suppressed (Fig. 2C) , indicating that MO1 can recognize smarcal1 mRNA efficiently (Eisen and Smith, 2008 ). Next, we tested the efficiency of MO2, which was designed to retain exon2. Using primers in exon1 and exon4, a 640 bp band was detected from WT embryos, but a 570-bp product was yielded in the MO2 morphants (Fig. 2D) , suggesting MO2 efficiently blocks splicing of smarcal1 mRNA.
We tested a series of dosages of MO1 (1 ng, 2 ng, 4 ng, 6 ng per embryo) and found no obvious defect in zebrafish gross morphology at the time points we examined (24 hpf, 2 dpf and 4 dpf). Among embryos injected with 8 ng smarcal1 MO1, we also did not observe obvious gross morphological abnormality during the first 24 h (Figs. 3A-C) . However, at 2 days post-fertilization (dpf), developmental defects were readily observed in smarcal1 MO1 morphants with shorter trunk (32/109, 2.17 ± 0.10 μm compared with 2.59 ± 0.09 μm in control MO injected embryos, P b 0.001), un-consumed yolk sac (99/109), less dark pigment (105/109) and heart edema (101/109) when compared to wild type (WT) and control MO injected embryos. Examples are shown in Figs. 3D-F and the percentage of embryos affected by the injection is shown inSupplementary Fig. S3B . By 4 dpf, the smarcal1 morphants had severe gross morphological defects (data not shown). We observed death in part of smarcal1 morphants (death 70/99). The rest of the morphants (growth delayed) could not hatch (26/29), and displayed heart edema (28/29) and shorter trunk and smaller head and eyes (23/29). Also, when compared to the heart rate of the control MO injected embryos (128.9 ± 6.5 times/min,Supplementary movie 1), the morphants exhibited lower heart rates (24/29, 59.2 ± 20.2 times/min,Supplementary movie 2).
In order to confirm MO1 specificity, we then tested MO2 effects. We found that like MO1, MO2 did not cause abnormal development at 24 hpf but led similar phenotypes at 2 dpf ( Supplementary Fig. S3A, B) . To further rule out the non-specific effects of smarcal1 MOs, we introduced five-nucleotide silent mutations into the full-length zebrafish smarcal1 mRNA (Eisen and Smith, 2008) . The primers are shown in Table 2 . Injection of 200 pg silent smarcal1 mRNA alone did not cause phenotype in embryos (data not shown). We co-injected 200 pg of this mRNA with smarcal1 MO1 and found that the developmental defects mentioned above were largely corrected ( Supplementary Fig. S3A, B) . Similarly, co-injection of smarcal1 mRNA and MO2 partially rescued the defects in MO2 morphants ( Supplementary Fig. S3B ). These results confirmed the specificity of smarcal1 MOs.
Alcian blue staining revealed that cartilage developed normally in WT and control MO injected zebrafish larvae at 5 dpf ( Supplementary  Fig. S4A-D) . In contrast, severely reduced growth of pharyngeal cartilage was found in smarcal1 morphants ( Supplementary Fig. S4E , F). The ceratobranchials 3-5 were absent, whereas the sizes of the dorsal hyosymplectic cartilage, the ventral ceratohyal and the jaw palatoquadrate were reduced ( Supplementary Fig. S4E, F) , suggesting that the maturation of arch cartilage requires smarcal1.
SIOD patients suffer migraine, cerebral ischaemia and transient ischemic attacks, all of which may be the result of arteriosclerosis in the first decade of life, suggesting defects in blood vessel formation and/or maintenance. We then examined whether knockdown of smarcal1 causes developmental defects in vasculogenesis and/or angiogenesis. At 2 dpf zebrafish embryos, the intact dorsal aorta and axial circulation were observed in smarcal1 morphants (data not shown), suggesting that the smarcal1 is not essential for vasculogenesis. The formation of the parachordal vessel (PAV) and sub-intestinal vessel (SIV) is a process of angiogenesis (Isogai et al., 2003; Nicoli and Presta, 2007) . Microangiography showed that both PAV and SIV were sprouted normally at uninjected and control MO embryos, whereas they were absent in smarcal1 morphants (19/20) at 3 dpf (Supplementary Fig. S4G-I ), suggesting that smarcal1 is required for angiogenesis.
Knockdown of smarcal1 impairs hematopoietic development
Using O-dianisidine staining, we found that there were fewer red blood cells in smarcal1 morphants at 2 dpf (35/40) (Fig. 3I ) compared to uninjected (Fig. 3G ) and control MO injected embryos (Fig. 3H) , suggesting an impaired erythrogenesis caused by knockdown of smarcal1.
To address effects of smarcal1 on hematopoiesis, WISH was performed to examine the expression of blood markers in smarcal1 morphants. The expression of scl and gata2, the hemangioblast and hematopoietic stem cell markers (Amatruda and Zon, 1999; Patterson et al., 2007; Yamauchi et al., 2006) , respectively, remained intact in smarcal1 morphants (Figs. 4A, B , and E, F), indicating that smarcal1 is not required for proliferation of hemangioblasts and hematopoietic stem cells. Although the initiation of primitive erythropoiesis is normal, the expression of gata1, that determines the fate of erythroid progenitor cells (Amatruda and Zon, 1999) , was markedly reduced in smarcal1 morphants (28/30, Figs. 4C, G) . Consistently, the expression of mature erythrocyte marker βE1-globin was also reduced (32/33, Figs. 4D, H). Real-time RT-PCR confirmed that gata1 and βE1-globin mRNA levels were significantly reduced at 24 hpf smarcal1 morphant (Fig. 4I) . These results indicate that deficiency of smarcal1 causes abnormal proliferation and/or differentiation of erythroid progenitors. To test whether the primitive myelopoiesis is impaired in smarcal1 morphants, the myeloid markers were assayed in 18 hpf embryos. The expressions of myeloid progenitor marker pu.1, monocyte/macrophage marker l-plastin and granulocyte marker mpo (Bennett et al., 2001) were generally normal (Figs. 4J, O) , indicating that smarcal1 is not required for the primitive myelopoiesis.
Next, we examined whether deficiency of smarcal1 affects definitive hematopoiesis. RT-PCR results showed that the expression of definitive hematopoietic marker runx1 (Kalev-Zylinska et al., 2002; Lam et al., 2009 ) was suppressed by smarcal1 knockdown at 24 hpf embryos (Fig. 4P) . WISH showed the expression of rag1, a thymic marker (Langenau and Zon, 2005) , was reduced (23/25, data not shown), suggesting the loss of the thymocytes in smarcal1 morphants. The defects in definitive myelopoiesis were examined at 30 hpf embryos. The expressions of pu.1 (38/40, Figs. 4Q, T), l-plastin (37/37, Figs. 4R, U) and mpo (32/36, Figs. 4S, V) were suppressed at ICM of 30 hpf smarcal1 morphants.
Knockdown of smarcal1 reduces cell proliferation and induces apoptosis
The development of the organisms depends on the balance between cell proliferation and apoptosis. Based on many lines of SIOD clinical evidence, we hypothesized that smarcal1 is involved in the cell cycle regulation. To examine cell proliferation changes in smarcal1 deficient embryos, we incorporated the S-phase marker of cell cycle BrdU into the DNA of embryos and found that the number of BrdU-positive nuclei in 20 hpf smarcal1 morphants were largely reduced (Figs. 5A, B, E, F) , even though there was no gross morphology The gross morphology of 1 dpf and 2 dpf smarcal1 morphants. The morphology of uninjected and control MO injected embryos (8 ng per embryo) was largely normal. By 2 dpf, the embryos injected with smarcal1 MO (8 ng per embryo) showed growth defects including less dark pigment, unconsumed yolk sac and heart edema (F). (G-I) O-dianisidine staining of 2 dpf embryos showed reduced hemoglobin-positive cells on the yolk in smarcal1 morphants (I). Anterior is to the left. change at this time point (see Fig. 3C ). By 2 dpf, a significant reduction of BrdU-positive nuclei was also observed in the head, eyes, yolk sac, ICM and tail in smarcal1 morphants (Figs. 5C, D, G, H) . The quantification of BrdU-positive nuclei in 2 dpf embryo head is shown at Fig. 5I . We further examined changes in the number of G2/M phase cells using immunostaining of phosphorylated histone 3 (pH3), which is phosphorylated in G2/M and is dephosphorylated in anaphase (Hendzel et al., 1997 ). As we found in BrdU staining, the numbers of pH3-positive cells were also significantly reduced by knockdown of smarcal1 at both 20 hpf and 2 dpf embryos (Figs. 5J, Q) .
The quantification of pH3-positive nuclei in 2 dpf embryo head is shown in Fig. 5R . To assay the cell cycle, DNA content of the cells from 2 dpf embryos was analyzed by Fluorescence Activated Cell Sorting (FACS). Propidium iodide (PI) staining showed that uninjected and control MO embryos displayed 62% and 60% of cells at G0/G1, 15% and 16% at S, and 23% and 23% at G2/M phase, respectively, whereas the smarcal1 morphants exhibited cell accumulation at G0/G1 phase (91%) and reduction at both S (5%) and G2/M (4%) phase (Fig. 5S) . These results indicate that cell cycle was arrested at G0/G1 phase in smarcal1 morphants. To examine whether the deficiency of smarcal1 causes apoptosis, TUNEL was used to detect apoptotic cells in zebrafish embryos. While the number of TUNEL positive cells in 14 hpf embryos remained unchanged (Figs. 5T, X) , it was significantly increased in 20 hpf smarcal1 morphants (Figs. 5U, Y) , even though there was no obvious abnormality of gross morphology at this time point (see Fig. 3C ). By 36 hpf, the number of positive cells was dramatically increased in the brain, eyes, trunk, tail and ICM (Figs. 5V, W, Z, Z'), suggesting that the developmental defects of smarcal1 morphants may be partially caused by the increase of apoptosis.
The cell cycle transition depends on the function of CDK-cyclin complexes. To explore whether deficiency of smarcal1 causes changes in the expression of cell cycle genes, we assayed the expression of a group of cyclins by real-time RT-PCR. We found that mRNA levels of cyclinA2, that promotes G1 to S phase transition (Lehner and O'Farrell, 1989; Sprenger et al., 1997) , were reduced significantly in both 1 dpf and 2 dpf smarcal1 morphants (Fig. 6A) . The expression levels of cyclinB1, cyclinD1 and cyclinE were not altered markedly at 1 dpf, but the mRNA levels of cyclinD1 were increased at 2 dpf morphants. These results are consistent with reduction of BrdU-positive cells in smarcal1 morphants ( Fig. 5I) . The cell cycle is also negatively regulated by cyclin-dependent kinase inhibitor proteins (kips/cips) p21cip1 (p21), p27kip1 (cdkn1b) and p57kip2 (cdkn1c), all of which are expressed at G1 phase (Vidal and Koff, 2000) . It is known that p21cip1 inhibits the cell cycle transition from G1 to S phase and controls the cell cycle exit to G0. We found that p21 mRNA level was greatly increased at 1 dpf and 2 dpf embryos by knockdown of smarcal1 (Fig. 6B) , whereas p27kip1 and 
regions of S. (S) FACS analysis with
PI staining of DNA contents shows that uninjected and control MO injected embryos had normal cell cycle, whereas the smarcal1 morphants showed cell accumulation at G0/G1 phase and cell reduction of S and G2/M phase at 2 dpf. (T-Z') Apoptosis analysis with TUNEL staining of smarcal1 morphants at 14 hpf (T, X), 20 hpf (U, Y) and 36 hpf (V, Z). (W, Z') are higher magnification of the boxed regions in (V) and (Z), respectively. All experiments were repeated at least three times. p57kip2 expressions were not significantly changed (Fig. 6B) . Collectively, our data imply that G0/G1 phase arrest in smarcal1 morphants may be caused by reduced expression of cyclinA2 and increased expression of p21.
Previous studies suggested that 15-20% of MOs used in zebrafish can induce neural death at 24 hpf or earlier stages through the activation of p53 signaling (Ekker and Larson, 2001; Robu et al., 2007) . Co-injection with p53 MO could rescue the neural death caused by those MOs (Bill et al., 2008; Gongal and Waskiewicz, 2008; Jia et al., 2008; Robu et al., 2007 ). Thus we co-injected p53 MO with smarcal1 MO to exclude the possibility that smarcal1 MO may have such offtargeting effects on p53 signaling. We observed that knockdown of p53 did not cause obvious developmental defects (data not shown), consistent with that p53 mutations did not affect the embryonic development in zebrafish (Berghmans et al., 2005) . We found that the gross morphology, erythrogenesis and apoptosis of co-injected embryos were not obviously changed when compared to smarcal1 morphants ( Supplementary Fig 5) . To test the efficiency of p53 MO, we injected 3 ng of mdm2 MO and found that mdm2 MO caused early apoptosis in 24 hpf zebrafish embryos ( Supplementary Fig 3C) , consistent with a previous report (Robu et al., 2007) . Co-injection of p53 MO significantly reduced apoptosis induced by mdm2 MO (Supplementary Fig 3C) , indicating p53 MO effectively inhibits p53 signaling, the abnormalities observed in smarcal1 morphants are not due to the p53 signaling activation, and the apoptosis in smarcal1 morphants may be p53-independent.
SMARCAL1 is down-regulated by E2F6
The involvement of smarcal1 in cell cycle regulation prompted us to investigate the association between smarcal1 and E2F6, a cell cycle regulating transcription factor. We used S_Site 1.0 (http://compel. bionet.nsc.ru/FunSite/SiteScan.html) to search for E2F binding sites at SMARCAL1 promoter. At human SMARCAL1 promoter, a 869 bp CpG island, usually associated with gene promoter and found at almost all house-keeping genes (Cho and Hedrick, 1997) , was identified between −933 to −1801. Three putative E2F binding sites were found between − 1250 to −1261 (site A), − 1069 to −1080 (site B) and − 965 to −976 (site C), respectively. In zebrafish, four e2f binding sites were found (Supplementary Fig. S6 ). To investigate whether E2Fs bind to these sites, EMSA was performed with use of biotin labeled E2F binding probes and nuclear protein extracts from E2F1-6 and dp1 co-transfected 293T cells. While E2Fs were not found to bind with site B and site C (data not shown), E2F6 but not E2F1-5 bound to site A (Fig. 7A) . This binding was completely reduced by unlabeled probes (Fig. 7A) . The results suggest that SMARCAL1 is a direct target of E2F6.
To test whether E2F6 activates or suppresses SMARCAL1 transcription, SMARCAL1 promoter sequence containing E2F binding sites (P1) was cloned into pGL3 vector, and the luciferase reporter assay was carried out. We found that E2F6 significantly suppressed SMARCAL1 transactivity by over-expression of E2F6 (Fig. 7B) . In contrast, transactivity of SMARCAL1 promoter sequence without E2F binding sites (P2) was not altered (Fig. 7B) . To validate this point, SMARCAL1 mRNA level was examined in E2F6 transfected 293T cells by RT-PCR. Over-expression of E2F6 decreased SMARCAL1 expression (Figs. 7C, D) . These results indicate that E2F6 is a transcriptional suppressor of SMARCAL1.
To further address whether E2F6 inhibits smarcal1 expression in vivo, we injected E2F6 mRNA into 1-2 cell zebrafish embryos. E2F6 mRNA injection significantly disrupted zebrafish development with phenotypes similar to those observed in smarcal1 morphants (Figs. 7E, F ). Consistently, smarcal1 transcription level was markedly inhibited in E2F6 mRNA injected embryos at 1 dpf (Figs. 7G, H) . These results suggest that smarcal1 may play important roles downstream to E2F6 in cell cycle regulation.
Discussion
Smarcal1 loss of function in zebrafish resembles SIOD symptoms
In this work, we first identified a zebrafish structural and functional homologue of the human SMARCAL1 gene. Structural analysis showed that the zebrafish smarcal1 shares 78.5% and 68% similarity to human and mouse homologues, respectively. This high degree of sequence similarity indicates functional conservation. Similar to its human and mouse counterparts (Boerkoel et al., 2002; Elizondo et al., 2006) , zebrafish smarcal1 is expressed ubiquitously at embryonic stages, implying a wide range of functions of smarcal1 during development.
SIOD patients have multiple developmental defects such as growth retardation, lymphopenia, bone marrow failure, anemia, neutropenia, craniofacial abnormality, renal failure and premature death in their first decades of life. An animal model is fundamentally important for understanding the cellular and molecular bases of SIOD and functions of SMARCAL1. In the present work, we found that knockdown of smarcal1 in zebrafish caused multi-system developmental defects, including growth retardation, craniofacial abnormality, reduced thymic development, and defects in both primitive and definitive hematopoiesis and angiogenesis. SIOD is considered a postnatal Fig. 6 . Knockdown of smarcal1 changes the expressions of cell cycle-related genes. Real-time PCR experiments show that mRNA levels of cyclinA (A) was suppressed and p21 (B) was increased by smarcal1 MO at 1 dpf and 2 dpf. The levels of cyclinB1, cyclinD1, cyclinE were not changed at 1 dpf, whereas the expressions of cyclinD1 increased at 2 dpf (A). The expression levels of cdkn1b (p27) and cdkn1c (p57) remained no significant change (B). The results were obtained from at least three experiments. β-actin mRNA was measured as an internal control. Data are presented as means ± SE. ⁎P b 0.05; ⁎⁎P b 0.01. developmental disease (Boerkoel et al., 2002) , though SMARCAL1 is expressed in all tissues at high levels in very early stages of human embryonic development (Deguchi et al., 2008) . Similarly, zebrafish smarcal1 transcript is expressed ubiquitously in the zebrafish embryos from the 1-cell stage, but gross morphological abnormalities caused by knockdown of smarcal1 were only observed after 24 hpf. It indicates that knockdown of smarcal1 in zebrafish can recapitulate SIOD symptoms.
We provided several lines of evidence to demonstrate the specificity of smarcal1 MOs. First, two MOs designed to block the translation and splicing of smarcal1, respectively, led to similar phenotypes. In contrast, embryos injected with a standard control MO developed normally. Second, the two MOs could efficiently knock down smarcal1 (see Fig. 2 ). Third, full-length smarcal1 with silent mutations largely rescued the phenotypes of MO1 and partially rescued the phenotypes of MO2 (seeSupplementary Fig.  S3B ). Taken together, zebrafish smarcal1 morphant can serve as an animal model to study the cellular and molecular mechanisms underlying SIOD.
Smarcal1 is required for hematopoiesis
In this work, we showed that impaired hematopoiesis is one of the major defects induced by smarcal1 deficiency. Previous studies have shown that chromatin remodeling molecules play important roles in the hematopoietic stem cell self-renewal, multilineage differentiation (Horsfield et al., 2007; Yoshida et al., 2008) , primitive and definitive alpha-and beta-globin transcription, primitive erythrocyte apoptosis (Griffin et al., 2008) and T-cell differentiation (Sawalha, 2008) , indicating that chromatin remodeling molecules are important regulators in hematopoiesis. We demonstrated a link between smarcal1 and hematopoiesis during zebrafish development. We found that the expressions of gata1, beta-E1 globin and runx1 in smarcal1 morphants were suppressed, indicating abnormal proliferation of both primitive and definitive erythroid progenitors. Similarly, smarcal1 is required for the proliferation of definitive myeloid cells and lymphocyte since the expressions of pu.1, l-plastin and mpo and rag1 were decreased by knockdown of smarcal1. Our results are consistent with the findings that SWI/SNF molecules play crucial roles in a wide variety of developmental processes during hematopoiesis via gene transcription regulation.
Smarcal1 is required for cell cycle progress SMARCAL1 encodes an ATPase-dependent chromatin remodeling molecule that contains all functional domains of SWI/SNF members. SWI/SNF family chromatin remodeling complexes promote or inhibit the transcriptional activity and are involved in cell cycle regulation through DNA methylation, acetylation, ubiqulation and phosphorylation, DNA repair, DNA replication and DNA recombination (Gangaraju and Bartholomew, 2007; Huang et al., 2003; Kadam and Emerson, 2002) . Recent study has shown that SMARCAL1 has DNA annealing helicase activity (Yusufzai and Kadonaga, 2008) that may contribute to the helicity of DNA at gene promoters. DNA superhelicity is a major regulator of gene expression in bacteria (Cheung et al., 2003; Dai and Rothman-Denes, 1999; Salmon et al., 2003) . Changing the level of DNA superhelicity could enhance or inhibit gene expression (Lim et al., 2003) . Deficiency of smarcal1 may result either in inappropriate or suppressed gene expression linked to the cell cycle. It implies that SIOD symptoms may be due to cell cycle defects caused by loss of SMARCAL1.
Our main finding is the demonstration of involvement of smarcal1 in cell cycle regulation. First, the cell cycle S phase marker BrdU incorporation and G2/M phase marker phosphorylated histone-3 signal were significantly reduced in smarcal1 morphants. Meanwhile, FACS experiments showed that the cell cycle was arrested at G0/G1 phase, indicating that deficiency of smarcal1 causes defects in G1/S phase transition. Second, the expression of the cell cycle molecule cyclinA2, which promotes G1 to S phase transition (Lehner and O'Farrell, 1989; Sprenger et al., 1997) , was suppressed, while CDK inhibitor A (p21), which is an inhibitor of G1 to S transition (Vidal and Koff, 2000) , was up-regulated. This indicates that smarcal1 modulates the cell cycle through transcriptional regulation similar to other SWI/ SNF family members (Gangaraju and Bartholomew, 2007; Kadam and Emerson, 2002) . Finally, smarcal1 morphants exhibit p53 independent cell death, suggesting the developmental defects of smarcal1 morphants may be partially caused by excessive apoptosis. Thus smarcal1 is required for cell cycle check point transition, which may be the cellular basis of SIOD.
Smarcal1 is a direct target of E2F6
E2F transcription factors regulate the expression of genes essential for the cell cycle transition, DNA replication, DNA synthesis, DNA repair and mitosis, and thus play crucial roles in cell proliferation, differentiation and apoptosis (DeGregori and Johnson, 2006; Korenjak and Brehm, 2005; Wu et al., 2001) . Deletion of E2Fs causes hematopoietic progenitor and immune cell deficiency by disruption of the cell cycle, resulting in anemia and leucopenia (Gabellini et al., 2006; Korenjak and Brehm, 2005) . E2F1-5 serve as both transcriptional activators and suppressors, whereas E2F6 suppresses E2F-responsive genes (Ogawa et al., 2002; Trimarchi et al., 1998) . Our data demonstrate that smarcal1 is a direct target of E2F6. First, the EMSA experiment showed E2F6 protein specifically bound to E2F site in SMARCAL1 promoter, and this binding could be inhibited completely by an unlabelled probe. Second, reporter gene analysis confirmed that SMARCAL1 was suppressed by over-expression of E2F6 both in vitro and in vivo. Third, over-expression of E2F6 reduced transcription levels of SMARCAL1 both in vivo and in vitro. These results further support that smarcal1 is a cell cycle regulator.
In summary, we cloned the zebrafish homologue of human SMARCAL1 gene and found that smarcal1 loss of function recapitulated the symptoms of SIOD patients with respect to growth retardation, blood cell deficiency, craniofacial abnormality and angiogenesis defect. It indicates that zebrafish can serve as an animal model for studying the mechanism of SIOD. Furthermore, we demonstrated that smarcal1 is involved in cell cycle regulation during development. Taken together, our study indicates that SIOD may be caused by cell proliferation defects and excessive apoptosis resulting from SMAR-CAL1 mutations.
